Last reviewed · How we verify

NCT04635878: INFLA-SEPSIS

INFLAmmasomes NLRP3 in Platelets and Leukocytes During SEPSIS in Intensive Care Unit

Completed Last updated 25 September 2024
What this trial tests

trial testing Blood collection in Sepsis in 11 participants. Completed in 30 May 2023.

Timeline
27 July 2020
Primary endpoint
30 May 2023
30 May 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
StatusCompleted
Study typeOBSERVATIONAL
Enrollment11
Start date27 July 2020
Primary completion30 May 2023
Estimated completion30 May 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

18 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

septic shock is the first cause of mortality in intensive care unit. Innate immunity is the body's first line of defense against pathogens

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood collection

Trials testing the same drug.

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04635878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing